624
Participants
Start Date
March 9, 2011
Primary Completion Date
November 30, 2016
Study Completion Date
November 30, 2016
REVLIMID®
The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
Dexamethasone
The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
Hallym University Sacred Heart Hospital, Anyang
Soon Chun Hyang University Hospital Bucheon, Bucheon-si
Wonju Severance Christian Hospital, Wŏnju
Chungnam National University Hospital, Daejeon
Kyungpook National University Hospital, Daegu
Ulsan University Hospital, Ulsan
Inje University Busan Paik Hospital, Busan
Inje University Haeundae Paik Hospital, Busan
Dong-a University Medical Center, Busan
Pusan National University Hospital, Busan
Kosin University Gospel Hospital, Busan
Pusan National University Yangsan Hospital, Yangsan
Chonbuk National University Hospital, Jeonju
Hwasun Chonnam National University Hospital, Hwasun-gun
Inje University Sanggye Paik Hospital, Seoul
Korea University Anam Hospital, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Seoul
Konkuk University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul
Boramae Medical Center, Seoul
Ewha Womans University Mokdong Hospital, Seoul
Korea University Guro Hospital, Seoul
Lead Sponsor
Celgene
INDUSTRY